Karius Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 179

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $100M

  • Investors
  • 20

Karius General Information

Description

Operator of a clinical laboratory testing center intended to focus on generating genomic insights for infectious diseases. The company's tests map each patient's microbial landscape from a single blood draw and develop molecular biology and data analysis tools that use deep sequencing to detect minuscule traces of microbial deoxyribonucleic acid directly from blood, enabling physicians to make rapid life-saving treatment decisions in a hassle-free manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Corporate Office
  • 975 Island Drive
  • Suite 101
  • Redwood City, CA 94065
  • United States
+1 (866) 000-0000

Karius Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karius Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 02-May-2024 $100M 00000 00000 Completed Generating Revenue
6. Debt - General 01-Jan-2024 0000 00000 Completed Generating Revenue
5. Later Stage VC (Series B) 07-Mar-2022 00000 00000 00000 Completed Generating Revenue
4. Debt - General 29-Nov-2018 0000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 07-Aug-2017 0000 000.00 00000 Completed Generating Revenue
2. Accelerator/Incubator $5.27M Completed Startup
1. Seed Round 20-Oct-2014 $5.27M $5.27M 000.00 Completed Startup
To view Karius’s complete valuation and funding history, request access »

Karius Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series BB 000,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series AA 4,421,354 $0.000100 $0.1 $3.37 $3.37 1x $0.32 8.05%
Series SS 380,401 $0.000100 $0.29 $1.31 $1.31 1x $0.32 0.27%
To view Karius’s complete cap table history, request access »

Karius Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical laboratory testing center intended to focus on generating genomic insights for infectious disease
Biotechnology
Redwood City, CA
179 As of 2024
00000
00000 0000-00-00
00000000000 00000

000000

ptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000 00000000
San Diego, CA
00 As of 0000
00000
000000000000 00000

000000

s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000000000000
Castel Maggiore, Italy
00000 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Karius Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocept Formerly VC-backed San Diego, CA 00 00000 000000000000 00000
Menarini Silicon Biosystems Formerly VC-backed Castel Maggiore, Italy 00000 000.00 000000&0 000.00
CosmosID Formerly VC-backed Germantown, MD 00 000.00 000000&0 000.00
Rheonix Venture Capital-Backed Ithaca, NY 00 00000 00000000000 00000
Phase Genomics Venture Capital-Backed Seattle, WA 00 00.000 0000000000 00.000
You’re viewing 5 of 16 competitors. Get the full list »

Karius Patents

Karius Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4291683-A1 Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease Pending 12-Feb-2021 0000000000
CA-3207956-A1 Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease Pending 12-Feb-2021 0000000000
EP-4274913-A1 Rapid, non-invasive detection and serial monitoring of infections in subjects using microbial cell-free dna sequencing Pending 11-Jan-2021 000000000
US-20240150851-A1 Rapid, non-invasive detection and serial monitoring of infections in subjects using microbial cell-free dna sequencing Pending 11-Jan-2021 000000000
EP-4263866-A1 Sequencing microbial cell-free nucleic acids to detect inflammation, secondary infection, and disease severity Pending 21-Dec-2020 C40B40/06
To view Karius’s complete patent history, request access »

Karius Executive Team (14)

Name Title Board Seat Contact Info
Alec Ford Chief Executive Officer
William Quirk Chief Financial Officer
Steve Malaska Chief Legal Officer
Stacy Solorio Chief People Officer
Tim Blauwkamp Ph.D Co-Founder, Chief Scientific Officer & Board Member
You’re viewing 5 of 14 executive team members. Get the full list »

Karius Board Members (9)

Name Representing Role Since
Alexander Morgan Ph.D Khosla Ventures Board Member 000 0000
Andrew Booth 5AM Ventures Board Member 000 0000
Elizabeth O'Farrell Self Board Member 000 0000
Joep Muijrers Ph.D Gilde Healthcare Board Member 000 0000
Norman Sharpless MD Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Karius Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karius Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Blue Water Life Science Fund Hedge Fund Minority 000 0000 000000 0
Gilde Healthcare Venture Capital Minority 000 0000 000000 0
Seventure Partners Venture Capital Minority 000 0000 000000 0
Waycross Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Karius FAQs

  • When was Karius founded?

    Karius was founded in 2014.

  • Who is the founder of Karius?

    Mickey Kertesz Ph.D and Tim Blauwkamp Ph.D are the founders of Karius.

  • Who is the CEO of Karius?

    Alec Ford is the CEO of Karius.

  • Where is Karius headquartered?

    Karius is headquartered in Redwood City, CA.

  • What is the size of Karius?

    Karius has 179 total employees.

  • What industry is Karius in?

    Karius’s primary industry is Biotechnology.

  • Is Karius a private or public company?

    Karius is a Private company.

  • What is the current valuation of Karius?

    The current valuation of Karius is 00000.

  • What is Karius’s current revenue?

    The current revenue for Karius is 00000.

  • How much funding has Karius raised over time?

    Karius has raised $409M.

  • Who are Karius’s investors?

    5AM Ventures, Blue Water Life Science Fund, Gilde Healthcare, Seventure Partners, and Waycross Ventures are 5 of 20 investors who have invested in Karius.

  • Who are Karius’s competitors?

    Biocept, Menarini Silicon Biosystems, CosmosID, Rheonix, and Phase Genomics are some of the 16 competitors of Karius.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »